

Dear Editor,

Thank you for carefully reviewing our manuscript previously titled “**Biclonal multiple myeloma of IgD-  $\lambda + \lambda$  : A case report**” for possible publication in the *World J Clin Cases*. We are grateful to you and your reviewers for their constructive critique. Those comments are valuable and very helpful for revising and improving our paper, as well as the important guiding significance to our researches. We have studied the reviewers' comments carefully and have made corrections which we hope be approval. We have revised the manuscript, highlighting our revisions in yellow, and have attached point-by-point responses detailing how we have revised the manuscript in response to the reviewers' comments below.

Thank you for your consideration and further review of our manuscript. Please do not hesitate to contact us with any further questions or recommendations. We are looking forward to hearing good news from you.

Yours Sincerely,

Q.- L. HE, Department of Clinical Laboratory, Translational medicine center, Huaihe Hospital of Henan University, 115 Ximen Street, Kaifeng City, Henan Province, China

Dr. X.-H. LIN, Department of Clinical Laboratory, Translational medicine center, Huaihe Hospital of Henan University, 115 Ximen Street, Kaifeng City, Henan Province, China

Reviewers:

This is an extension of the study of their previous publication. At the superficial level, it seemed to be good, but there were major issues in this manuscript, as stated below:

1) Page 3, Line 3: “is an infrequent subtype of” – use “a rare subtype.”

Answer: Thank you for your suggestion. We have revised the sentence “Immunoglobulin D (IgD) multiple myeloma is a rare subtype of multiple myeloma and commonly occurs in younger subjects but at a later stage of the International Staging System (ISS) when admitted” in page 3, line 3.

2) P3, L5: “of International Staging System (ISS)” – use “of the.”

Answer: Thank you for your comment. We have modified the sentence “Immunoglobulin D (IgD) multiple myeloma is a rare subtype of multiple myeloma and commonly occurs in younger subjects but at a later stage of the International Staging System (ISS) when admitted” in page 3, line 5 according to your suggestion.

3) P3: “IgD- $\lambda + \lambda$  biclonal MM are rarer” – Use “is rarer.”

Answer: Thank you for your suggestion. We have revised the sentence “As a special type of IgD myeloma, IgD-  $\lambda + \lambda$  biclonal MM is rarer” in page 3, line 6.

4) P3, L23-24: “in antisera to IgD region” - Use “in the.”

Answer: Thank you for your comment. We have modified the sentence “Serum IFE indicated an over-representation of lambda light chain and yielded two monoclonal bands in  $\lambda$  region but only one corresponding heavy chain band in the antisera to IgD region” in page 3, line 22 according to your suggestion.

5) P4, L9: “IgD- $\lambda$ + $\lambda$  myeloma are extremely rare and has a later ISS.” Use is, not are.

Answer: Thank you for your comment. We are terribly sorry for our carelessness. According to your suggestion, we have revised the sentence “IgD-  $\lambda$  +  $\lambda$  myeloma is extremely rare and has a later ISS stage at diagnosis” in page 4, line 6.

6) P4, “a more complete serum IFE.” Delete “more.”

Answer: Thank you for your suggestion. We have deleted “more” in the sentence. Please see it in page 4, line 11.

7) P4, L13: “IgD-  $\lambda$  +  $\lambda$  myeloma as other isotypes” - use “different” not “other.”

Answer: Thank you for your comment. We have amended the sentence “Furthermore, the laboratory examination tends to consider IgD-  $\lambda$  +  $\lambda$  myeloma as different isotypes in that its serum IFE shows two bands in the  $\lambda$  region but no responding heavy chain band” in page 4, line 10.

8) P5, L4: “a increasing tendency” - use an not a.

Answer: Thank you for your suggestion. We are terribly sorry for our carelessness. According to your suggestion, we have made a correction in the sentence. Please find the change in page 5, line 3.

9) P5, L9-11: monoclonal should be followed by “;” not comma “,” to join two separate independent clauses.

Answer: Thank you for your suggestion. We have amended the punctuation in the sentence “The majority of MM are monoclonal; only precious few MM are biconal, which almost all belong to the heavy chain type, such as IgG+IgA, IgG+IgM, and IgG+IgG” in page 5, line 9.

10) P6, L15: “a severe anemia” - delete a.

Answer: Thank you for your suggestion. We have deleted “a” in the sentence “The peripheral blood examination in the local hospital indicated severe anemia with hemoglobin 54 g/L and a potential malignant tumor from the blood system” in page 6, line 12.

11) P6, L16: “potential malignant tumor” - use potentially.

Answer: Thank you for your comment. According to your suggestion, we have corrected the word “potential” in the sentence to “potentially” in page 6, line 13.

**12)** P6, L23-24: “No history of exposure to industrial poisons or radioactive substances, and no history of smoking or alcohol use”  
- use a complete sentence.

Answer: Thank you for your comment. According to your suggestion, a complete expression in the sentence is used in page 6, line 20-21.

**13)** P8, L7: “monoclonal bands in  $\lambda$  region” - use the before “ $\lambda$  region.”

Answer: Thank you for your suggestion. We have added “the” before “ $\lambda$  region” .Please find the change in page 8, line 6.

**14)** P10, L8-9: “blood tumor mutant group” - use the before blood.

Answer: Thank you for your suggestion. We have added “the” in the sentence “Gene analysis of the blood tumor mutant group was mainly normal” in page 9, line 13.

**15)** Fig 2. “Figure 2 Bone marrow cytomorphologic examination( $\times 1000$ ) showed a large of immature plasma cells.” An arrowhead should be used to point to the cells of interest.

Answer: Thank you for your comment. We have marked an arrowhead to point the immature plasma cells in Figure 2. Please see the revision in page 9, line 15 and line 16.

**16)** Figure 3 Flow cytometry(BD FACSDiva 8.0.2) suggested an elevation of monoclonal plasma cells. They need to label the numbers with bar graphs to illustrate the elevation value.

Answer: Thank you for your comments. According to your suggestion, the percentage of positive cells has been labeled in Figure 3, please see page 10. In addition, because the lack of control, the present data is not suitable for bar graphs to illustrate the elevation value.

**17)** P12, L19: “from lung infection in the ensuing” - use a before lung.

Answer: Thank you for your suggestion. We have amended the sentence “Unfortunately, the patient died from a lung infection in the ensuing 2 months” in page 11, line 13.

**18)** P13, L22: “as a standard diagnostic items of” - use “as standard diagnostic items of.”

Answer: Thank you for your suggestion. We have delete “a” in the sentence “In view of the infrequency of IgD myeloma, most hospitals or laboratories do not set the antisera to IgD as standard diagnostic items of serum IFE” in page 12, line 10.

**19)** P13, L28: “with a light chain myeloma or monoclonal myeloma” – delete a.

Answer: Thank you for your suggestion. We have delete “a” in the sentence “Thus, the diagnosis of type IgD-  $\lambda + \lambda$  myeloma is apt to be missed or confused with light chain myeloma or monoclonal myeloma” in page12, line 15.

**20)** P15, L25-27: Revised to “a later disease stage with a more aggressive course of the disease, younger affected subjects have been noticed at diagnosis of IgD myeloma.”

Answer: Thank you for your comment. According to your suggestion, we have revised the sentence “Moreover, a later disease stage with a more aggressive course of the disease, younger affected subjects have been noticed at diagnosis of IgD myeloma” in page 14, line 8-10.